Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Children with High-Risk Neuroblastoma Using a Reduced-Intensity Conditioning Regimen: Results from the AIEOP trial

Neuroblastoma (NB) represents the most frequent extra-cranial pediatric tumor and the most common solid tumor in children aged less than 5 years1. Patients with high-risk (HR) disease, most of which have metastatic disease at presentation, are particularly challenging2 –5. Current multimodal protocols for HR NB include multiagent chemotherapy, surgical resection of the primary site, autologous hematopoietic stem cell transplantation (auto-HCT), and radiotherapy6. In a large retrospective study by the Children's Oncology Group, HR NB patients exhibited a 5-year e vent-free survival rate of 50.8%7.

Source: Biology of Blood and Marrow Transplantation - March 7, 2024 Category: Hematology Authors: Arcangelo Prete, Edoardo Lanino, Francesco Saglio, Alessandra Biffi, Elisabetta Calore, Maura Faraci, Roberto Rondelli, Claudio Favre, Marco Zecca, Gabriella Casazza, Fulvio Porta, Roberto Luksch, Simone Cesaro, Marco Rabusin, Rosanna Parasole, Rosa Maria Source Type: research